Mavyret is intended to treat adults with all types of chronic hepatitis C virus with mild or no cirrhosis who have not previously received treatment for the illness. Patients with moderate to severe kidney disease, individuals on dialysis and genotype 1 patients unsuccessfully treated with a different drug are also eligible for treatment.
Mavyret represents the first drug for all hepatitis C genotypes with an eight-week treatment duration. Previously, the standard treatment length for the disease was at least 12 weeks.
More articles on supply chain:
4 latest FDA approvals
Senate passes FDA user fee reauthorization bill
How retail pharmacies are driving down generic drug prices: 3 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
